PRESENTATION

Q1 2026 — Results presentation

Q1 2026PDF · 28 pages3.9 MB


-- 1 of 28 --

st
April 14, 2026

-- 2 of 28 --

Cautionary note on Forward-looking statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to
applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased
scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from
the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in
the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and
other filings with the Securities and Exchange Commission. Copies of these filings are available online at 	www.sec.gov, 	www.jnj.com, 	investor.jnj.com, 	or on request from Johnson & Johnson.
Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of
new information or future events or developments.
Cautionary note on Non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website.
3

-- 3 of 28 --

IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab
A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc.
relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.; bleximenib R&D co-funding agreement with Blackstone Life Sciences
Oncology
REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology; ICOTYDE was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and
commercialize for a broad range of indications; JNJ-4804 R&D co-funding agreement with Royalty Pharma plc
Immunology
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and
RISPERDAL CONSTA developed in collaboration with Alkermes, Inc.	Neuroscience
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK., INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with
Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc.; UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion
agreement with Nippon Shinyaku in Japan
Other
Strategic partnerships, collaborations
& licensing arrangements
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:
4

-- 4 of 28 --

CEO Remarks
Sales performance and earnings review
Capital allocation and guidance update
Q&A
Agenda
5
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Darren Snellgrove
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech
1
2
3
4

-- 5 of 28 --

Joaquin Duato
Chairman and Chief Executive Officer

-- 6 of 28 --

7
Q1 Earnings Summary
operational sales
growth1,2
Six key businesses driving growth
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Includes an approximate (540) basis point headwind from STELARA

-- 7 of 28 --

Innovative Medicine: 7.4% operational sales growth1,2
8
Oncology 	Neuroscience	Immunology
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Includes an approximate (920) basis point headwind from STELARA
Note: Includes existing products and planned future launches

-- 8 of 28 --

9
ICOTYDE 	U.S. FDA approval brings new option
for first-line systemic treatment of plaque psoriasis
Preferred first line systemic treatment for patients 12
and older with moderate to severe plaque psoriasis
No mandatory TB test or lab monitoring
Full launch occurred immediately on approval
Potential to revolutionize how psoriatic disease is treated
First and only IL-23R targeted oral peptide to deliver complete
skin clearance and favorable safety profile in a once-daily pill
Immunology

-- 9 of 28 --

Innovative Medicine: 7.4% operational sales growth1,2
10
Oncology 	Neuroscience	Immunology
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Includes an approximate (920) basis point headwind from STELARA
Note: Includes existing products and planned future launches

-- 10 of 28 --

MedTech: 4.6% operational sales growth1
11
Cardiovascular 	Surgery 	Vision
VARIPULSE 	Platform 	Dual Energy THERMOCOOL
SMARTTOUCH 	SF Catheter
Shockwave Intravascular
Lithotripsy System
OMNYPULSE
Catheter
Impella® Heart
Pump Technology
OTTAVA
Robotic
Surgical
System
ETHICON 	4000
Surgical Stapler
ACUVUE® OASYS 1-Day Family
TECNIS Odyssey 	TECNIS PureSee
MONARCH
Platform
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Includes existing products and planned future launches

-- 11 of 28 --

12	Note: related to sales; excludes the impact of translational currency

-- 12 of 28 --

Darren Snellgrove
Vice President,
Investor Relations

-- 13 of 28 --

% Change
Q1 2025	Q1 2026	Regional sales results 	Operational1
Reported
8.3%	8.3%	$12.3	$13.3	U.S.
2.7	14.5	5.1	5.8	Europe
2.5	10.8	1.2	1.3
Western Hemisphere
(ex U.S.)
6.1	8.5	3.3	3.6	Asia-Pacific, Africa
3.9	11.9	9.6	10.7	International
6.4%	9.9%	$21.9	$24.1	Worldwide (WW)
Dollars in billions
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded
1st Quarter 2026 sales
14

-- 14 of 28 --

$24.1 $21.9
$6.6 	$6.7
(2.5)%; 	(7.2)%1
$2.70 	$2.77
Dollars in billions, except EPS
Reported %; 	Operational %1
Sales
Adjusted earnings2 	Adjusted EPS2
9.9%; 	6.4%1
GAAP earnings
(1.4)%
Q1 2026 	Q1 2025
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
1st Quarter 2026 financial highlights
GAAP EPS
15
Q1 2026 	Q1 2025 	Q1 2026 	Q1 2025
Q1 2026 	Q1 2025 	Q1 2026 	Q1 2025
(52.4)% 	(52.9)%
$5.2
$11.0
$2.14
$4.54

-- 15 of 28 --

Other
$2,899
Neuroscience
$2,175
Oncology
$6,973 Immunology
$3,380
■ 	Reported growth 	■ 	Operational growth1
$15,426
11.2%, 	7.4%
WW sales $MM
Key drivers of operational performance1
• 	DARZALEX increase primarily driven by strong share gains and market growth,
partially offset by inventory dynamics
• 	CARVYKTI increase driven by share gains and continued site expansion
• 	TECVAYLI growth driven by launch uptake and share gains from expansion in the
community setting and recent U.S. TECVAYLI + DARZALEX FASPRO approval
• 	TALVEY growth driven by share gains from expansion in the community setting
• 	RYBREVANT/LAZCLUZE growth driven by launch uptake and share gains
• 	ERLEADA increase driven by continued share gains in mCSPC and market growth
• 	IMBRUVICA decrease driven by share loss due to continued competitive pressure
and unfavorable patient mix
Oncology
• 	TREMFYA growth due to share gains across all indications with significant IBD launch
momentum and market growth
• 	SIMPONI/SIMPONI ARIA and REMICADE decrease driven by share loss, biosimilar
competition, and unfavorable patient mix, partially offset by market growth
• 	STELARA decline driven by the impact of biosimilar competition, increasing adoption
of novel classes, and unfavorable patient mix
Immunology
• 	SPRAVATO growth driven by continued increased physician and patient demand
• 	CAPLYTA driven by strong continued momentum in the aMDD launch
• 	INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA increase primarily
driven by favorable patient mix
Neuroscience
• 	UPTRAVI increase driven by market and share growth, partially offset by inventory
dynamics
• 	OPSUMIT/OPSYNVI growth driven by share gains, market growth, and favorable
patient mix
• 	PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA increase driven by favorable
patient mix
• 	XARELTO decrease driven by continued share erosion
Other
Adjusted operational sales2: WW: 5.6%, U.S. 6.3%, Int’l 4.5%
Innovative Medicine highlights – 1st quarter 2026
WW 11.2%, U.S. 9.6%, Int’l 13.4%	Reported:
WW 7.4%, U.S. 9.6%, Int’l 4.3%	Operational1:
(8.8)%, 	(11.8)%
22.8%, 	17.8%
2.1%, 	(0.9)%
Strong operational growth1 of 7.4% driven primarily by Oncology and Neuroscience
32.0%, 	29.3%
16
Stelara impacted results1 	by ~(920) basis points
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded

-- 16 of 28 --

Key drivers of operational performance1
• 	Electrophysiology: Increase driven by procedure growth, commercial execution, new
product performance (VARIPULSE, TRUPULSE, NUVISION and CRYSTAL), and OUS
inventory dynamics, partially offset by competitive pressures in PFA
• 	Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and
Impella CP
• 	Shockwave: 	Double digit growth driven by strong adoption of Coronary and
Peripheral portfolios and new product launches (JAVELIN & E8)
Cardiovascular
• 	Advanced:
• 	Biosurgery: 	~ +5% growth driven by continued strength of the portfolio and
commercial execution, partially offset by the impact of the surgery
transformation program and VBP in China
• 	Endocutters: 	~ -3% due to competitive pressures and VBP in China
• 	Energy: 	~ +2% increase driven by new product launches, partially offset by VBP in
China
• 	General: 	Increase primarily due to technology penetration and upgrades within our
differentiated Wound Closure portfolio (Barbed & PLUS Sutures) and market
expansion, offset by OUS tender timing
Surgery
• 	Contact Lenses/Other: 	Increase driven by strong performance of the ACUVUE
OASYS 1-Day family of products and strategic price actions, partially offset by
inventory dynamics OUS
• 	Surgical: 	Growth driven by strength of recent product innovations, robust demand for
premium IOLs, and strong commercial execution, partially offset by competitive
pressures in the U.S.
Vision
Growth across all platforms primarily driven by new product launches and strong
commercial execution:
• 	Hips: 	Increase driven by new product launches (EMPHASYS)
• 	Knees: 	Increase driven by strength of the ATTUNE portfolio, in part driven by pull
through related to the VELYS Robotic assisted solutions
• 	Trauma: 	Growth driven by recently launched products (VOLT)
• 	Spine, Sports & Other: 	New product innovations (TriAltis) and growth in shoulders,
offset by competitive pressures and inventory dynamics
Orthopaedics
Adjusted operational sales2: WW 4.7%, U.S. 6.1%, Int’l 3.2%
Surgery
$2,511
Orthopaedics
$2,383
Vision
$1,365
Cardiovascular
$2,377
■ 	Reported growth 	■ 	Operational growth1
$8,636
7.7%, 	4.6%
WW sales $MM
Solid operational growth1 of 4.6% due to commercial execution and innovation
WW 7.7%, U.S. 5.9%, Int’l 9.7%	Reported:
WW 4.6%, U.S. 5.9%, Int’l 3.2%	Operational1:
13.0%, 	10.5%
6.7%, 	3.6%
4.8%, 	1.2%
6.3%, 	3.2%
MedTech highlights – 1st quarter 2026
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded 	17

-- 17 of 28 --

%
Increase
(Decrease)
2025	2026
% to Sales	Amount	% to Sales	Amount
9.9	100.0	$21,893	100.0	$24,062	Sales to customers
10.2	33.6	7,357	33.7	8,106	Cost of products sold
9.8	66.4	14,536	66.3	15,956	Gross Profit
18.0	23.3	5,112	25.1	6,034	Selling, marketing and administrative expenses
9.4	14.7	3,225	14.7	3,527	Research and development expense
-	-	0.1	36	In-process research and development impairments
(0.6)	(128)	0.2	43	Interest (income) expense, net
(33.4)	(7,321)	1.2	294	Other (income) expense, net
0.1	17	0.1	32	Restructuring
(56.1)	62.3	13,631	24.9	5,990	Earnings before provision for taxes on income
(71.3)	12.1	2,632	3.1	755	Provision for taxes on income
(52.4)	50.2	$10,999	21.8	$5,235	Net Earnings
(52.9)	$4.54	$2.14	Net earnings per share (Diluted)
2,423.8	2,445.2	Average shares outstanding (Diluted)
19.3%	12.6%	Effective tax rate
Adjusted earnings before provision for taxes and net earnings1
(2.4)	36.6	$8,011	32.5	$7,821	Earnings before provision for taxes on income
(1.4)	30.6	$6,706	27.5	$6,614	Net earnings
(2.5)	$2.77	$2.70	Net earnings per share (Diluted)
16.3%	15.4%	Effective tax rate
1 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
(Unaudited; Dollar and shares in millions except per share figures)
18
1st Quarter 2026
Condensed consolidated statement of earnings

-- 18 of 28 --

%
Increase
(Decrease)
2025	2026
Innovative Medicine % to Sales	Amount	% to Sales	Amount
11.2	100.0	$13,873	100.0	$15,426	Sales to customers
7.3	24.3	3,371	23.4	3,617	Cost of products sold
12.4	75.7	10,502	76.6	$11,809	Gross Profit
29.1	16.3	2,261	18.9	2,918	Selling, marketing and administrative expenses
10.4	18.4	2,548	18.2	2,813	Research and development expense
(1.5)	(204)	(0.2)	(43)	Other segment items 	1
3.8	42.5	5,897	39.7	$6,121	Adjusted segment income before tax 	2
(Unaudited; Dollar in millions)
Adjusted earnings before provision for taxes on income by segment
19
%
Increase
(Decrease)
2025	2026
MedTech % to Sales	Amount	% to Sales	Amount
7.7	100.0	8,020	100.0	$8,636	Sales to customers
14.2	34.8	2,795	37.0	3,192	Cost of products sold
4.2	65.2	5,225	63.0	$5,444	Gross Profit
9.4	33.1	2,656	33.6	2,906	Selling, marketing and administrative expenses
6.4	8.4	671	8.3	714	Research and development expense
(2.2)	(182)	(1.2)	(98)	Other segment items 	1
(7.6)	25.9	2,080	22.3	$1,922	Adjusted segment income before tax 	2
%
Increase
(Decrease)
2025	2026
Enterprise % to Sales	Amount	% to Sales	Amount
(2.4)	36.6	$8,011	32.5	$7,821	Adjusted income before tax 	2
1st Quarter 2026
1 	Includes other Income and Expense
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the 	company's website

-- 19 of 28 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 20 of 28 --

Capital allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
Higher
priority
Lower
priority
Investment in M&A
Q1 2026	Dollars in billions
$22.1
Cash and marketable
securities
($55.0)	Debt
($32.9)	Net debt
~$1.5	Free cash flow1,2
Q1 2026:
$3.5B 	invested in R&D
$3.1B 	in dividends paid
to shareholders
Note: Values may be rounded
1 	Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment
2 	Estimated as of April 14, 2026. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
Note: Values may be rounded
Capital allocation strategy
21

-- 21 of 28 --

Operational2 sales guidance of 6.4% and adjusted operational EPS2,4 at 5.7% (midpoints)
Comments	January 2026	April 2026
Increasing midpoint to 6.1%	5.4% - 6.4%	5.6% - 6.6%	Adjusted operational sales1,2
Increasing midpoint by $0.2B to 6.4%
$99.5B - $100.5B
5.7% - 6.7%
$99.7B - $100.7B
5.9% - 6.9%
Operational sales2
Increasing midpoint by $0.3B to 7.0%
Incremental FX impact of $0.1B or 0.1%
$100.0B - $101.0B
6.2% - 7.2%
$100.3B - $101.3B
6.5% - 7.5%
Estimated reported sales 	3
Maintaining	Increase of at least 50 bps	Increase of at least 50 bps
Adjusted pre-tax
operating margin4,5
Maintaining	$1.0 - $1.2 billion	$1.0 - $1.2 billion	Net other income4
Maintaining	$300 - $400 million	$300 - $400 million	Net interest expense / (income)
Maintaining	17.5% - 18.5%	17.5% - 18.5%	Effective tax rate4
Increasing midpoint by $0.02 to 5.7%
$11.28 - $11.48
4.5% - 6.5%
$11.30 - $11.50
4.7% - 6.7%
Adjusted EPS (operational)2,4
Increasing midpoint by $0.02 to 7.1%
Maintaining FX impact of $0.15 or 1.4%
$11.43 - $11.63
5.9% - 7.9%
$11.45 - $11.65
6.1% - 8.1%
Adjusted EPS (reported)3,4
2026 P&L guidance
1 	Non-GAAP measure; excludes acquisitions and divestitures 	4 	Non-GAAP measure; excludes intangible amortization expense and special items
2 	Non-GAAP measure; excludes the impact of translational currency 	5 	Sales less: COGS, SM&A and R&D expenses
3 	Calculated using Euro Average Rate: April 2026 = $1.17 and January 2026 = $ 1.17
Note: Values may be rounded 	22

-- 22 of 28 --

Innovative
Medicine
• 	Expect more pronounced impact from newly launched products as the year progresses
• 	Anticipate generic competition for OPSUMIT (second half in U.S.) and SIMPONI (first half in EU; potentially second half in U.S.)
• 	Expect impact of voluntary agreement with the U.S. government to be evenly distributed throughout the year
• 	Expect continued acceleration of newly launched products as the year progresses with normalized seasonality
• 	Surgery Transformation sales headwinds expected to increase through the year
• 	Anticipate additional rounds of VBP in China throughout the year, heavier in the second half of the year
Phasing Considerations
MedTech
• 	Expect heavier investment in the first half of the year
• 	Intra-Cellular benefit laps in Q2
• 	Anticipate higher earnings per share growth in the second half of the year compared to the first half
P&L
23
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Anticipate fairly consistent operational1 sales growth in the first and second half; 53rd week impacts the second half

-- 23 of 28 --

Innovative Medicine
Anticipated 2026 milestones1 driving long-term value creation
MedTech
24
ICOTYDE in PsO
TECVAYLI + DARZALEX in RRMM
TREMFYA in PsA SD
TECVAYLI in RRMM
INLEXZO in HR NMIBC
nipocalimab in WAIHA and SLE
CAPLYTA in bipolar mania
JNJ-4804
ERLEADA in LPC & HRPC
OTTAVA
ETHIZIA
STSF Dual Energy Catheter
C2 Aero Catheters
TECNIS PureSee IOL
ATTUNE Hinge
VOLT
MONARCH Urology
VARIPULSE Pro
1 	List above is not inclusive of all 2026 anticipated milestones across approvals, planned submissions, potential clinical data presentations, and launches
PsO: Psoriasis; RRMM: Relapsed/refractory multiple myeloma; PsA SD: Psoriatic arthritis structural damage; HR NMIBC: High-risk non-muscle invasive bladder cancer; WAIHA: Warm autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; LPC: Localized prostate cancer; HRPC: High-risk
prostate cancer; STSF: SMARTTOUCH Surround Flow; IOL: Intraocular lens

-- 24 of 28 --

Save the Date
25
Enterprise Business Review
Save the Date
Tuesday, December 8, 2026
Innovative
Medicine MedTech
Surgery 	Vision	Cardiovascular	Oncology 	Neuroscience	Immunology

-- 25 of 28 --

Q&A
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Darren Snellgrove
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 26 of 28 --

Slide footer goes here if required 	27

-- 27 of 28 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
US 	TREMFYA (guselkumab) 	P 	US 	nipocalimab 	US 	ERLEADA (apalutamide) 	P 	ICOTYDE (icotrokinra) 	ERLEADA (apalutamide) 	JNJ-4804 Co-antibody Therapy
Psoriatic Arthritis Structural
Damage (APEX)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
EU 	Localized Prostate Cancer
(ATLAS)
Psoriasis (ICONIC-ADVANCE
1&2 Update)
Localized Prostate Cancer (ATLAS) 	Ulcerative Colitis (DUET-UC)
P 	US 	ICOTYDE (icotrokinra) 	US 	CAPLYTA (lumateperone) 	US 	ERLEADA (apalutamide) 	ICOTYDE (icotrokinra) 	ERLEADA (apalutamide) 	JNJ-4804 Co-antibody Therapy
EU 	Psoriasis (ICONIC) 	Bipolar Mania 	EU 	High Risk Prostate Cancer
(PROTEUS)
Psoriasis (ICONIC-ASCEND) 	High Risk Prostate Cancer
(PROTEUS)
Crohn's Disease (DUET-CD)
AKEEGA (niraparib/abiraterone) 	US 	bleximenib 	icotrokinra 	TALVEY (talquetamab) 	JNJ-4804 Co-antibody Therapy
EU 	M1 Metastatic Castration-
Sensitive Prostate Cancer
(AMPLITUDE)
Relapsed Refractory Acute
Myeloid Leukemia (cAMeLot-1)
Psoriatic Arthritis (ICONIC-PsA) 	Relapsed Refractory Multiple
Myeloma A-CD38 Naïve
(MonumenTAL-3)
Psoriatic Arthritis (AFFINITY)
P 	US 	DARZALEX (daratumumab) 	P 	US 	TALVEY (talquetamab) 	ICOTYDE (icotrokinra) 	TECVAYLI (teclistamab) 	nipocalimab
Frontline multiple myeloma
transplant ineligible (CEPHEUS)
P 	EU 	Relapsed Refractory Multiple
Myeloma A-CD38 Naïve
(MonumenTAL-3)
Psoriasis (ICONIC-TOTAL
Update)
Relapsed Refractory Multiple
Myeloma CD38 exposed (MajesTEC-
9)
Systemic Lupus Erythematosus
(JASMINE)
P 	US 	TECVAYLI (teclistamab) 	P 	US 	TECVAYLI (teclistamab) 	CAPLYTA (lumateperone)
INLEXZO (gemcitabine intravesical
delivery system) 	bleximenib
EU 	Multiple Myeloma 1-3PLs
(MajesTEC-3)
P 	EU 	Relapsed Refractory Multiple
Myeloma CD38 exposed
(MajesTEC-9)
Bipolar Mania (ITI-007-452) 	High Risk Non Muscle Invasive
Bladder Cancer BCG Experienced
(SunRISe-5)
Relapsed Refractory Acute
Myeloid Leukemia (cAMeLot-1)
TECVAYLI (teclistamab) 	TECVAYLI (teclistamab) 	nipocalimab 	JNJ-1887 	sCD59
EU 	Relapsed Refractory Multiple
Myeloma CD38 exposed
(MajesTEC-9)
P 	EU 	Multiple Myeloma 1-3PLs
(MajesTEC-3)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
Geographic Atrophy (PARASOL)
US
INLEXZO (gemcitabine
intravesical delivery system)
EU 	High Risk Non Muscle Invasive
Bladder Cancer BCG
Experienced (SunRISe-5)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2026*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs
and assets and does not guarantee continued investment. This information is as of April 14, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
= 	Achieved

-- 28 of 28 --